AGEN

[stock-kitty]

AGEN sure looks like it has a little more upside.


Cheers

[setravis]

Back above the 13 and 50-day MA


52wk Range: 1.38 - 5.42
Volume: 1,244,983
Avg Vol (3m): 1,271,840

Technicals
Last Price Quote is:
8.48%above 13-day MA
13.92%above 50-day MA
RS Rating: 98 

Fundamentals
Key Data:
Market Cap (M): $144.09 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: 08/07/2007
Last Analyst Rating: Sell

[rud56789]

This says a lot, 5.1M from CEO at a 40 percent premium.  His base salary in 2006 was $420,000 per annum with a target bonus of 50% of base salary.

There are 5.2 million in short interest, this could be a significant squeeze on a drug approval. 

The company has some revenue from Glaxo for using their QS-21 in phase III clinical trials of a malaria vaccine.  There are also many other large pharms using the QS-21 in Phase I - Phase 3 trials. 

Shares outstanding:47.55 million

Market cap: $109.37M (09/10/07)


Antigenics, Armen Raise $26 Million for Cancer Drug Development
2008-01-09 07:01 (New York)

By Luke Timmerman
Jan. 9 (Bloomberg) -- Antigenics Inc., the developer of a therapy that stimulates the immune system to fight cancer, raised $26 million from private investors, including $5.1 million from its chief executive officer.

Antigenics agreed to sell 8.7 million shares at $3, which is 40 percent higher than its closing price yesterday, the New York- based biotechnology company said in an e-mailed statement. For each share purchased, investors got one warrant, which gives them the right to buy another share at $3 for 10 years. Antigenics CEO Garo Armen paid more than market price to invest so he could get the warrants, which should be valuable if the company reaches its goals this year, he said in a telephone interview. Antigenics aims to win clearance from Russian regulators to market its first product, Oncophage, before the end of June. It could generate $100 million in sales if approved.

``We're making a bet that there's significant upside to this company,'' Armen said. Antigenics fell 1 cent to $2.15 yesterday in Nasdaq Stock Market composite trading. The stock has gained 9.7 percent in the past 12 months.

The Invus Group, a New York-based fund with $4 billion under management, was the lead investor in the round. Oracle Partners also participated.

[setravis]

lets watch and see if we have anything cooking on this one...